1 2	Resting-State EEG Reveals Regional Brain Activity Correlates in Alzheimer's and Frontotemporal Dementia
3	
4	
5	Ali Azargoonjahromi ¹ *, Hamide Nasiri ² , Fatemeh Abutalebian ³
6	
7	¹ Shiraz University of Medical Sciences, Shiraz, Iran. <u>aazargoonj@gmail.com</u>
8	² School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran. <u>hnasiri@sina.zums.ac.ir</u>
9	³ Department of Biotechnology and Medicine, Islamic Azad University of Tehran Central Branch,
10	Tehran, Iran. fatemeh.abutalebian@gmail.com
11	
12	*Corresponding author: Ali Azargoonjahromi
13	E-mail: <u>aazargoonj@gmail.com</u>
14	ORCID: 0000-0002-6997-9419
15	
16	
17	
18	
19	
20	
21	

Page 1 of 25

22 Abstract

23 Resting-state EEG records brain activity when awake but not engaged in tasks, analyzing frequency bands 24 linked to cognitive states. Recent studies on Alzheimer's disease (AD) and frontotemporal dementia 25 (FTD) have found a link between EEG activity, MMSE scores, and age, though some findings are 26 conflicting. This study aimed to explore EEG regional differences among AD and FTD, thereby 27 improving diagnostic strategies. We analyzed EEG recordings from 88 participants in OpenNeuro Dataset 28 ds004504, collected at AHEPA General Hospital using a Nihon Kohden 2100 EEG device. The study 29 used preprocessed recordings, classification algorithms, and cognitive function assessments (MMSE) to 30 identify significant predictors and correlations between EEG measures and cognitive variables. The study 31 revealed that cognitive function, age, and brain activity show distinct relationships in AD and FTD. In 32 AD, MMSE scores significantly predicted brain activity in regions like C3, C4, T4, and Fz, with better 33 cognitive performance linked to higher EEG power in frontal and temporal areas. Conversely, age had a 34 major influence on brain activity in FTD, particularly in regions like C3, P3, O1, and O2, while MMSE 35 scores did not significantly predict brain activity. In FTD, higher EEG power in regions like P3, P4, Cz, 36 and Pz correlated with lower cognitive function. Thus, the findings suggest that EEG biomarkers can 37 enhance diagnostic strategies by highlighting different patterns of brain activity related to cognitive 38 function and age in AD and FTD.

Keywords: Electroencephalography; Alzheimer's disease; Resting-state EEG; Frontotemporal Dementia; Age; Cognitive Function.

- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48

49

50 **1. Introduction**

51 Resting-state EEG (electroencephalography) records brain activity when an individual is awake but not 52 engaged in specific tasks, analyzing delta, theta, alpha, beta, and gamma frequency bands linked to 53 various cognitive and physiological states [1-3]. It uses electrodes placed on the scalp according to the 54 international 10-20 system (e.g., Fp1, Fp2, F7, F3, Fz, F4, F8, T3, C3, Cz, C4, T4, T5, P3, Pz, P4, T6, O1, 55 O2) to detect microvolt-range electrical signals from neurons. These signals are amplified and analyzed to 56 study brain activity patterns, aiding in neurological diagnosis and monitoring changes over time. Indeed, 57 this non-invasive approach—resting-state EEG—is used to study the brain's baseline neural activity and 58 can provide valuable insights into various neurological and psychiatric conditions [4-6].

59 In recent times, the use of resting-state EEG for studying neurodegenerative diseases like Alzheimer's 60 disease (AD) [7-10] and frontotemporal dementia (FTD) [11-13] has gained prominence. Indeed, it 61 provides insights into the brain's electrical activity patterns associated with these conditions, potentially 62 revealing biomarkers that aid in diagnosis and monitoring disease progression. Studies have shown that 63 EEG can detect abnormalities in frequency bands alpha power and altered connectivity patterns in 64 patients with AD and FTD compared to healthy individuals. These findings contribute to understanding 65 how these diseases affect brain function and may help in developing new diagnostic tools and treatment 66 strategies [14-16].

The Mini-Mental State Examination (MMSE) is a widely used tool for assessing cognitive function and screening for cognitive impairment. It evaluates various cognitive domains, including orientation, attention, memory, language, and visuospatial skills. Research has shown significant correlations between MMSE scores and EEG activity at specific electrodes in patients with AD and FTD. These correlations help identify how cognitive functions are linked to brain activity patterns in these neurodegenerative diseases [17, 18].

In AD and FTD patients, frontal electrodes (Fp1, Fp2, F7, F3, Fz, F4, F8) have been found to correlate with MMSE scores, where lower scores are often associated with reduced EEG activity in these regions. These regions are crucial for executive functions, attention, and working memory, which are assessed by several MMSE tasks [19]. Similarly, temporal electrodes (T3, T4, T5, T6) show significant correlations with MMSE scores due to their involvement in memory and language functions [20]. Other EEG electrodes such as parietal (P3, Pz, P4), occipital (O1, O2), and central (C3, Cz, C4) electrodes are also linked to MMSE scores, with activity in these regions correlating with cognitive functions such as

visuospatial skills, calculation, visual processing, and motor control. In most studies, reduced activity in
these areas is associated with lower MMSE scores, indicating potential cognitive decline [21-23].

82 Another factor is age, which plays a crucial role in modulating brain activity and cognitive function [24]. 83 Aging can impact EEG patterns, leading to changes in frequency band power and connectivity that are 84 distinct from those observed in neurodegenerative diseases [25-27]. In both AD and FTD, age-related 85 changes in brain activity can complicate the interpretation of EEG findings. For instance, age-related 86 atrophy and functional decline can mask or exacerbate the abnormalities typically associated with these conditions [28, 29]. Noteworthy, studies have shown that age-related effects on EEG include decreased 87 88 alpha and beta power and altered connectivity patterns, which can be seen across various brain regions. 89 These changes may overlap with or confound the pathological changes observed in AD and FTD, making 90 it important to consider age when interpreting EEG data in these populations [30-32].

91 However, other research finds that age-related changes in brain activity are not always consistent across 92 different neurodegenerative conditions. For instance, in AD, age may interact with disease-specific 93 pathology, leading to complex and sometimes conflicting results about how age influences cognitive 94 function and brain activity compared to other conditions or in combination with other factors like genetic 95 predispositions and lifestyle [33-36].

96 Despite these findings, EEG recordings can still be influenced by patient population heterogeneity, 97 technical variability, inconsistent electrode placement, and comorbid conditions. The current study on 98 EEG recordings addressed these limitations by including participants with AD and FTD and using 99 standardized EEG protocols in a clinical setting. Differences in cognitive assessments and the absence of 100 longitudinal data pose challenges to tracking disease progression accurately. To minimize technical 101 variability, the current study implemented meticulous electrode placement, signal quality checks, and 102 robust preprocessing techniques, including Butterworth filtering, artifact removal via ASR and ICA, and 103 baseline correction.

104 The study aimed to explore the correlation between EEG measures across brain regions, cognitive 105 performance, and age in AD and FTD patients, aiming to identify EEG biomarkers to enhance diagnostic 106 strategies for neurodegenerative diseases.

2. Methods and Materials

The data presented in this article originates from the OpenNeuro Dataset ds004504, accessible via DOI:
 https://doi.org/10.18112/openneuro.ds004504.v1.0.7. As detailed by [37], this dataset encompasses EEG

resting state recordings with eyes closed from a total of 88 participants. Within this cohort, 36 individuals
were diagnosed with AD, 23 with FTD, and 29 were classified as CN. In the current study, we analyzed
the data obtained from individuals with AD and FTD.

113 **2.1. EEG Recording**

114 The dataset recordings were conducted to explore functional differences in EEG activity among AD, CN, 115 and FTD groups. These recordings were carried out in a clinical routine setting at the 2nd Department of

116 Neurology, AHEPA General Hospital of Thessaloniki, by a team of experienced neurologists. Using a

117 Nihon Kohden 2100 clinical EEG device, recordings were made with 19 scalp electrodes (Fp1, Fp2, F7,

118 F3, Fz, F4, F8, T3, C3, Cz, C4, T4, T5, P3, Pz, P4, T6, O1, and O2) and 2 electrodes (A1 and A2) placed

119 on the mastoids for impedance checking and as reference electrodes. The electrodes followed the 10–20

120 international system. (Figure 1)

EEG Electrode Positioning (10/20 System)



121



123 Recordings adhered to the clinical protocol, with participants sitting with their eyes closed. The referential

montage used Cz for common mode rejection, a sampling rate of 500 Hz, and a resolution of $10 \,\mu$ V/mm.

125 The recording durations varied: 13.5 minutes on average for the AD group (range: 5.1–21.3 minutes), 12

126 minutes for the FTD group (range: 7.9–16.9 minutes), and 13.8 minutes for the CN group (range: 12.5–

127 16.5 minutes). In total, the dataset comprises 485.5 minutes of AD recordings, 276.5 minutes of FTD128 recordings, and 402 minutes of CN recordings.

129 This study received approval from the Scientific and Ethics Committee of AHEPA University Hospital,

130 Aristotle University of Thessaloniki (protocol number 142/12-04-2023). The investigations conformed to

131 the principles outlined in the Declaration of Helsinki (1975), revised in 2008

132 (http://www.wma.net/en/30publications/10policies/b3/, accessed March 2019).

133 **2.2. Preprocessing**

The preprocessing of the EEG signals in this study focused exclusively on the derivatives folder, where 134 135 the preprocessed data is stored. Initially, a Butterworth band-pass filter with a frequency range of 0.5 to 136 45 Hz was applied to the signals. Following this, the signals were re-referenced to the average value of 137 electrodes A1 and A2. To handle artifacts, the ASR (Automatic Subspace Reconstruction) routine was employed to remove segments of data that exceeded a conservative threshold, specifically a 0.5-second 138 139 window with a standard deviation of 17. Subsequently, Independent Component Analysis (ICA) was 140 used, specifically the RunICA algorithm, to decompose the 19 EEG signals into 19 ICA components [38]. 141 Components identified as "eye artifacts" or "jaw artifacts" by the ICLabel method in the EEGLAB 142 platform were automatically excluded. Despite the recordings being in a resting state with participants' 143 eyes closed, eye movement artifacts were still detected in some EEG recordings. Figure 2 in the original 144 document visually demonstrates the difference between a raw signal and its preprocessed counterpart, 145 highlighting the removal of high-frequency artifacts and the application of baseline correction.

146 **2.3. Classification Benchmark**

To benchmark the classification performance of the EEG dataset for distinguishing between AD vs. CN and FTD vs. CN, a set of straightforward and reproducible feature extraction and classification techniques were employed. This approach ensures that the methods can be easily validated and extended by other researchers.

151 **2.3.1. Feature Extraction**

One of the primary features extracted for EEG classification tasks is the Relative Band Power (RBP) across five key frequency bands [39]: Delta (0.5–4 Hz), Theta (4–8 Hz), Alpha (8–13 Hz), Beta (13–25 Hz), and Gamma (25–45 Hz). The EEG signals were divided into 4-second epochs with a 50% overlap, and each epoch was labeled as AD, FTD, or CN. The Power Spectral Density (PSD) for each frequency band was calculated using the Welch method [40], which involves segmenting the signal, computing the

Page 6 of 25

squared magnitude of the discrete Fourier transform for each segment, and averaging the results. The
relative PSD for each band was then computed, resulting in a feature matrix with five features per epoch.
Figure 3 illustrates scalp heatmaps of PSD averaged across the AD, FTD, and CN groups, providing a

160 visual comparison of the PSD distribution for each frequency band.

161 **2.3.2.** Classification

162 To classify the EEG data for AD vs. CN and FTD vs. CN, several machine learning algorithms were 163 utilized. These included LightGBM, Multilayer Perceptron (MLP), Random Forests, Support Vector 164 Machine (SVM), and k-Nearest Neighbors (kNN). The classification performance was evaluated using 165 the Leave-One-Subject-Out (LOSO) validation method [39]. In this method, all epochs from one subject 166 are used as the test set, while epochs from the remaining subjects form the training set. This process is 167 repeated iteratively for each subject, and the average performance metrics-accuracy, sensitivity, 168 specificity, and F1 score—are calculated from the confusion matrix. This comprehensive benchmarking 169 provides a solid foundation for evaluating and comparing the performance of various classification 170 techniques on this EEG dataset.

171 **2.4. Cognitive Assessment**

The cognitive and neuropsychological status of the participants was assessed using the international MMSE [41]. This test evaluates various cognitive domains, including arithmetic, memory, orientation, language, and visuospatial skills. During the assessment, participants are asked a series of questions and given simple tasks to perform, such as naming objects, recalling a list of words, following basic instructions, and copying a design. The MMSE score ranges from 0 to 30, with higher scores indicating better cognitive function and lower scores indicating more severe cognitive decline.

178 **2.5. Statistical Analysis**

We used Python 3.11 to conduct a comprehensive analysis of EEG data from patients with AD and FTD. Our approach involved perform linear regression analyses, examining the relationships between logtransformed EEG measures and cognitive variables such as the MMSE, age, and gender. We assessed the impact of these variables on various EEG electrode sites by calculating adjusted R-squared values, beta coefficients, standard errors, 95% confidence intervals, and p-values. A p-value of less than 0.05 was considered statistically significant. Additionally, we employed correlation analysis to explore the strength of relationships between the MMSE scores and EEG measures, reporting p-values to determine statistical

significance. This analysis enabled us to identify significant predictors and correlations, providinginsights into how cognitive and demographic factors influence EEG patterns in AD and FTD patients.

188 **3. Results**

189 In the current study, participants were categorized into two groups: AD and FTD. The AD group 190 consisted of individuals diagnosed with AD without additional dementia-related comorbidities. The 191 average age of participants was 66.4 years (SD = 7.9) for the AD group and 63.6 years (SD = 8.2) for the 192 FTD group. There was no significant age difference between the groups. The analysis revealed a notable 193 difference in gender distribution, with a higher proportion of females in the AD group (66.7%) compared 194 to the FTD group (39.1%). EEG measurements indicated a significant difference in log power at the O2 195 electrode, with FTD patients showing lower values than their AD counterparts. All participant data was 196 anonymized in accordance with GDPR regulations to ensure the confidentiality and privacy of personal 197 information. (Table 1)

Table 1.: Demographic characteristics of the participants.

-	AD (n= 36)	FTD (n= 23)	P value
Age	$66.39{\pm}~7.89$	$63.95{\pm}~8.22$	0.206
Gender, F	24 (66.7)	9 (39.1)	0.038
MMSE	$17.75{\pm}~4.5$	$22.17{\pm}\ 2.64$	<0.001
Log Fp1	-18.34 ± 2.48	-18.86 ± 2.31	0.42
Log Fp2	$\textbf{-18.53}{\pm}\textbf{2.48}$	$-18.93{\pm}2.18$	0.525
Log F3	-17.66±2.48	-17.95 ± 2.37	0.655
Log F4	$\textbf{-17.94}{\pm}2.47$	-17.58 ± 2.43	0.586
Log C3	-18.06 ± 2.47	$\textbf{-18.88}{\pm}2.09$	0.19
Log C4	-17.96 ± 2.48	-18.58 ± 2.43	0.346
Log P3	$-18.30{\pm}2.52$	-18.82 ± 2.13	0.411
Log P4	$\textbf{-18.22}{\pm}\textbf{2.52}$	-19.09 ± 2.25	0.184
Log O1	$\textbf{-18.12}{\pm}2.46$	-18.63 ± 2.45	0.434
Log O2	$-17.80{\pm}2.52$	$-19.08{\pm}2.15$	0.049
Log F7	$\textbf{-18.02}{\pm}2.62$	$-18.19{\pm}2.51$	0.816
Log F8	$\textbf{-18.28}{\pm}\textbf{2.62}$	$\textbf{-18.25}{\pm}\textbf{2.51}$	0.965
Log T3	$\textbf{-18.02}{\pm}2.52$	$\textbf{-18.19}{\pm}2.39$	0.792
Log T4	$\textbf{-18.06}{\pm}2.56$	$\textbf{-18.91}{\pm}\textbf{2.47}$	0.215
Log T5	$\textbf{-18.30{\pm}~2.49}$	$\textbf{-18.39}{\pm}2.56$	0.894
Log T6	-17.91±2.43	$\textbf{-18.45}{\pm}\textbf{2.62}$	0.422
Log Fz	-17.74 ± 2.48	-18.13 ± 2.04	0.53
Log Cz	-18.14 ± 2.48	-18.22 ± 2.16	0.903
Log Pz	-18.20 ± 2.47	-18.44±2.18	0.696

AD: Alzheimer's Disease; FTD: Frontotemporal Dementia; MMSE: Mini-Mental State Examination.

200

We then employed a correlation coefficient among various EEG log-transformed power measurements and MMSE scores for individuals with AD. The correlations reflect how different EEG power measurements relate to each other and to cognitive function as assessed by the MMSE. Significant correlations are indicated by asterisks, with * representing p < 0.05 and ** representing p < 0.01.

205 The MMSE scores show positive correlations with several EEG regions, particularly Log Fp1, Log Fp2,

Log F4, Log T3, Log T4, and Log Fz. These correlations, ranging from 0.361 to 0.379, suggest that higher cognitive function, as measured by the MMSE, is associated with increased EEG power in these

areas. Notably, Log Fp1, Log T4, and Log Fz have significant correlations with MMSE scores (p < 0.05),

209 indicating that better cognitive performance is related to higher EEG power in these regions.

In terms of EEG power measures, the correlations are predominantly strong and significant across various
brain regions. For example, Log Fp1 shows robust positive correlations with Log Fp2 (0.764**), Log F3
(0.698**), and Log C3 (0.731**), highlighting a strong interrelationship among different EEG regions.
These high correlations suggest a coordinated pattern of EEG activity across the brain, which is consistent
in AD patients. (Table 2) (Figure 1)

215

216

217

218

219

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
1. MMSE	1.000	0.214	0.173	0.232	0.280	.379*	0.335	0.270	0.328	0.291	0.331	0.274	0.242	0.265	.361*	0.277	0.221	.360 [*]	0.277	0.239
2. Log Fp1	0.214	1.000	.764**	.698**	.820**	.731**	.758**	.836**	.730**	.798**	.767**	.802**	.910**	.856**	.765**	.741**	.736**	.651**	.722**	.774**
3. Log Fp2	0.173	.764**	1.000	.672**	.760**	.739**	.783**	.771**	.838**	.843**	.684**	.702**	.752**	.813**	.746**	.719**	.723**	.781**	.856**	.878**
4. Log F3	0.232	.698**	.672**	1.000	.818**	.877**	.911**	.783**	.754**	.867**	.793**	.825**	.734**	.855**	.854**	.855**	.762**	.876**	.839**	.824**
5. Log F4	0.280	.820**	.760**	.818**	1.000	.830**	.851**	.830**	.851**	.829**	.815**	.764**	.865**	.876**	.864**	.705**	.900**	.748**	.734**	.826**
6. Log C3	.379*	.731**	.739**	.877**	.830**	1.000	.877**	.898**	.866**	.849**	.755**	.793**	.759**	.791**	.864**	.901**	.808**	.912**	.877**	.849**
7. Log C4	0.335	.758**	.783**	.911**	.851**	.877**	1.000	.788**	.850**	.941**	.833**	.904**	.771**	.918**	.931**	.878**	.797**	.906**	.887**	.861**
8. Log P3	0.270	.836**	.771**	.783**	.830**	.898**	.788**	1.000	.868**	.778**	.810**	.734**	.873**	.820**	.801**	.887**	.837**	.795**	.774**	.873**
9. Log P4	0.328	.730**	.838**	.754**	.851**	.866**	.850**	.868**	1.000	.827**	.766**	.782**	.762**	.854**	.857**	.800**	.893**	.869**	.818**	.877**
10. Log O1	0.291	.798**	.843**	.867**	.829**	.849**	.941**	.778**	.827**	1.000	.801**	.869**	.808**	.903**	.868**	.848**	.769**	.884**	.878**	.912**
11. Log O2	0.331	.767**	.684**	.793**	.815**	.755**	.833**	.810**	.766**	.801**	1.000	.816**	.818**	.862**	.836**	.739**	.775**	.728**	.716**	.851**
12. Log F7	0.274	.802**	.702**	.825**	.764**	.793**	.904**	.734**	.782**	.869**	.816**	1.000	.685**	.927**	.818**	.816**	.723**	.826**	.880**	.837**
13. Log F8	0.242	.910**	.752**	.734**	.865**	.759**	.771**	.873**	.762**	.808**	.818**	.685**	1.000	.812**	.822**	.722**	.807**	.661**	.636**	.803**
14. Log T3	0.265	.856**	.813**	.855**	.876**	.791**	.918**	.820**	.854**	.903**	.862**	.927**	.812**	1.000	.874**	.824**	.803**	.832**	.861**	.900**
15. Log T4	.361*	.765**	.746**	.854**	.864**	.864**	.931**	.801**	.857**	.868**	.836**	.818**	.822**	.874**	1.000	.817**	.825**	.822**	.801**	.787**
16. Log T5	0.277	.741**	.719**	.855**	.705**	.901**	.878**	.887**	.800**	.848**	.739**	.816**	.722**	.824**	.817**	1.000	.723**	.883**	.868**	.824**
17. Log T6	0.221	.736**	.723**	.762**	.900**	.808**	.797**	.837**	.893**	.769**	.775**	.723**	.807**	.803**	.825**	.723**	1.000	.775**	.710***	.815**
18. Log Fz	.360*	.651**	.781 **	.876**	.748**	.912**	.906**	.795**	.869**	.884**	.728**	.826**	.661**	.832**	.822**	.883**	.775**	1.000	.929**	.876**
19. Log Cz	0.277	.722**	.856**	.839**	.734**	.877**	.887**	.774**	.818**	.878**	.716**	.880**	.636**	.861**	.801**	.868**	.710***	.929**	1.000	.884**
20. Log Pz	0.239	.774**	.878**	.824**	.826**	.849**	.861**	.873**	.877**	.912**	.851**	.837**	.803**	.900**	.787**	.824**	.815**	.876**	.884**	1.000

220 **Table 2.:** A correlation coefficient between various EEG electrodes and MMSE scores for individuals with AD.



222

223 Figure 1.: The heatmap reveals several variables with strong correlations to MMSE scores, a key measure of 224 cognitive performance in AD. The strongest correlations are with Log Fp1, Log Fp2, Log Fp3, Log Fp4, Log F3, 225 Log F4, Log F7, and Log F8, indicating that these EEG channels or frontal lobe regions are significant. Negative 226 correlations, shown in dark blue, suggest that higher EEG values in these frontal regions are linked to worse 227 cognitive performance or lower MMSE scores. This indicates that increased activity or abnormalities in the frontal 228 lobe might signal cognitive decline in AD. In contrast, variables with weaker correlations to MMSE scores include 229 Log Cz, Log Pz, Log T5, Log T6, Log O1, and Log O2, which relate to central, parietal, and occipital lobes. This 230 suggests that the frontal lobe is more crucial in cognitive performance and decline in AD patients.

231

For the FTD group, MMSE scores generally showed weak positive correlations with most EEG regions, but there were significant negative correlations with Log P3 (-0.234), Log P4 (-0.311), Log Cz (-0.376), and Log Pz (-0.344). These negative correlations suggest that higher EEG power in these specific regions is linked to lower cognitive function. In other words, increased activity in Log P3, Log P4, Log Cz, and Log Pz corresponds to poorer performance on the MMSE, indicating that these regions are particularly important for understanding cognitive decline.

238

- Additionally, the results revealed strong positive correlations among various EEG regions, indicating a
- 240 coordinated pattern of brain activity. For example, Log Fp1 showed significant positive correlations with
- 241 Log Fp2 (0.687**), Log F3 (0.594**), and Log C3 (0.637**), reflecting a high level of synchrony
- between these areas. Likewise, Log C3 and Log C4 demonstrated robust positive correlations with
- regions such as Log P3 (0.931**) and Log P4 (0.726**), suggesting a cohesive and interconnected
- network of EEG activity across these brain regions. The significant correlations are denoted by asterisks:
- 245 **p < 0.01 and *p < 0.05. (table 3) (figure 2)

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
1. MMSE	1.000	-0.030	0.039	0.250	0.057	-0.041	0.054	-0.234	-0.311	-0.014	-0.138	0.109	0.071	0.051	0.052	-0.054	-0.028	-0.064	-0.376	-0.344
2. Log Fp1	-0.030	1.000	.687**	.594**	.536*	.637**	.468*	.586**	.523*	.518*	.47 2*	.748**	.593**	.621**	.463*	.490 *	.460*	.769**	.613**	.649**
3. Log Fp2	0.039	.687**	1.000	.529*	0.423	.458*	0.309	0.395	0.377	0.307	0.278	.460 *	0.363	.487 *	0.210	0.360	0.347	.650**	.491*	.448*
4. Log F3	0.250	.594**	.529*	1.000	.906**	.584**	.823**	.507*	.469*	.856**	.456*	.896**	.830**	.911**	.778**	.838**	.824**	.524*	0.394	.496*
5. Log F4	0.057	.536*	0.423	.906**	1.000	.553**	.813**	.607**	.551**	.850**	.435*	.885**	.870**	.868**	.784**	.815**	.785**	.532*	$.517^{*}$	0.413
6. Log C3	-0.041	.637**	.458*	.584**	.553**	1.000	.785**	.931**	.825**	.594**	.847**	.568**	.625**	.735**	.695**	.658**	.661**	.797**	.741**	.783**
7. Log C4	0.054	.468*	0.309	.823**	.813**	.785**	1.000	.775**	.726**	.835**	.626**	.753**	.864**	.942**	.929**	.905**	.901**	.499*	.550**	.578**
8. Log P3	-0.234	.586**	0.395	$.507^{*}$.607**	.931**	.775**	1.000	.912**	.626**	.818**	.518*	.634**	.714**	.686**	.685**	.682**	.750**	.841**	.733**
9. Log P4	-0.311	.523*	0.377	.469*	.551**	.825**	.726**	.912**	1.000	.654**	.774**	.474*	.523*	.708**	.609**	.753**	.742**	.639**	.718**	.716**
10. Log O1	-0.014	.518*	0.307	.856**	.850**	.594**	.835**	.626**	.654**	1.000	.638**	.820**	.778**	.872**	.743**	.921**	.904**	0.388	0.421	.570**
11. Log O2	-0.138	. 47 2 [*]	0.278	.456*	.435*	.847**	.626**	.818**	.774**	.638**	1.000	0.422	.445*	.592**	.473 *	.642**	.621**	.675**	.573**	.720**
12. Log F7	0.109	.748**	.460 *	.896**	.885**	.568**	.753**	.518*	. 474 [*]	.820**	0.422	1.000	.864**	.849**	.749**	.748**	.711**	.549**	0.424	.496*
13. Log F8	0.071	.593**	0.363	.830**	.870**	.625**	.864**	.634**	.523*	.778**	.445*	.864**	1.000	.887**	.881**	.781**	.794**	.546*	.596**	.471*
14. Log T3	0.051	.621**	.487 *	.911**	.868**	.735**	.942**	.714**	.708**	.872**	.592**	.849**	.887**	1.000	.877**	.941**	.934**	.606**	.581**	.633**
15. Log T4	0.052	.463*	0.210	.778**	.784**	.695**	.929**	.686**	.609**	.743**	.473*	.749**	.881**	.877**	1.000	.825**	.841**	.479 *	$.527^{*}$.509*
16. Log T5	-0.054	.490*	0.360	.838**	.815**	.658**	.905**	.685**	.753**	.921**	.642**	.748**	.781**	.941**	.825**	1.000	.984**	.484*	.485*	.610**
17. Log T6	-0.028	.460*	0.347	.824**	.785**	.661**	.901**	.682**	.742**	.904**	.621**	.711**	.794**	.934**	.841**	.984**	1.000	.468*	.516*	.627**
18. Log Fz	-0.064	.769**	.650**	.524*	.532*	.797**	.499*	.750**	.639**	0.388	.675**	.549**	.546*	.606**	.47 9*	.484*	.468*	1.000	.778**	.674**
19. Log Cz	-0.376	.613**	.491*	0.394	.517*	.741**	.550**	.841**	.718**	0.421	.573**	0.424	.596**	.581**	$.527^{*}$.485*	.516*	.778**	1.000	.765**
20. Log Pz	-0.344	.649**	.448*	.496*	0.413	.783**	.578**	.733**	.716**	.570**	.720**	.496*	.471*	.633**	.509*	.610**	.627**	.674**	.765**	1.000

246 **Table 3.:** A correlation coefficient between various EEG electrodes and MMSE scores for individuals with FTD.



247

Figure 2.: The figure is a correlation matrix heatmap illustrating the relationships between MMSE scores and 248 various logarithmic EEG measures from different brain regions in FTD patients. The top row shows that the 249 250 strongest correlations with MMSE scores are found in the frontal lobe regions (Log Fp1, Log Fp2, Log F3, Log F4, 251 Log F7, Log F8), indicated by lighter colors, suggesting these areas are critical for cognitive performance. In 252 contrast, weaker correlations are observed in central, parietal, and occipital regions (Log C3, Log C4, Log P3, Log 253 P4, Log O1, Log O2, Log T3, Log T4, Log T5, Log T6, Log Fz, Log Cz, Log Pz), shown by darker colors, 254 indicating these areas are less influential in cognitive decline as measured by the MMSE. High inter-correlations 255 within the frontal lobe regions further emphasize their importance in cognitive function, potentially serving as 256 biomarkers for assessing cognitive health in FTD patients.

257

Using linear regression, we examined the relationship between EEG data from various brain channels and cognitive scores (MMSE), while accounting for age and gender. This analysis aimed to identify whether specific EEG patterns are associated with cognitive decline and how well these patterns predict changes in cognitive performance. (Table 4)

		AD						FTD				
Model	Adjusted R ²	B (S.E.)	β	95% CI		P value	Adjusted R ²	B (S.E.)	β	95% CI		P value
				lower	Upper	-	•	· · ·	•	lower	Upper	-
Log Fp1	0.025						0.012				**	
MMSE		0.118 (0.095)	1.241	-0.076	0.312	0.223		-0.028 (0.21)	-0.133	-0.467	0.412	0.896
Gender		-0.784 (0.87)	-0.9	-2.557	0.99	0.375		-0.285 (1.11)	-0.257	-2.61	2.039	0.8
Age		-0.074 (0.054)	-1.363	-0.184	0.036	0.182		0.103 (0.06)	1.732	-0.22	0.228	0.099
Log Fp2	-0.028						-0.032					
MMSE		0.098 (0.098)	0.994	-0.102	0.297	0.328		0.034 (0.202)	0.169	-0.389	0.458	0.868
Gender		-0.751 (0.897)	-0.838	-2.578	1.075	0.408		-0.917 (1.07)	-0.857	-3.156	1.323	0.402
Age		-0.032 (0.056)	0.58	-0.146	0.081	0.556		-0.068 (0.058)	1.173	-0.053	0.188	0.255
Log F3	-0.034						-0.07					
MMSE		0.133 (0.098)	1.351	-0.067	0.333	0.186		0.253 (0.224)	1.126	-0.217	0.732	0.274
Gender		0.052 (0.899)	0.058	-1.778	1.883	0.954		-1.127 (1.187)	-0.949	-3.612	1.358	0.354
Age		-0.026 (0.056)	-0.471	-0.14	0.088	0.641		-0.014 (0.064)	-0.22	-0.148	0.12	0.828
Log F4	0.044						-0.097					
MMSE		0.155 (0.094)	1.653	-0.036	0.347	0.108		0.058 (0.233)	0.248	-0.429	0.545	0.806
Gender		-0.58 (0.859)	-0.676	-2.329	1.169	0.504		-1.122 (1.231)	-0.911	-3.699	1.456	0.374
Age		-0.075 (0.053)	-1.409	-0.184	0.034	0.169		-0.032 (0.066)	-0.479	-0.17	0.107	0.638
Log C3	0.089						0.183					
MMSE		0.213 (0.0920	2.319	0.026	0.4	0.027		-0.031 (0.173)	-0.18	-0.394	0.331	0.859
Gender		-0.525 (0.841)	-0.624	-2.237	1.188	0.537		-0.704 (0.916)	-0.768	-2.621	1.213	0.452
Age		-0.054 (0.052)	-1.029	-0.16	0.053	0.311		0.126 (0.049)	2.559	0.023	0.229	0.019
Log C4	0.118						-0.1					
MMSE		0.19 (0.095)	2.012	-0.002	0.383	0.053		0.055 (0.233)	0.238	-0.432	0.543	0.815
Gender		-0.131 (0.865)	-0.151	-1.893	1.632	0.881		-0.704 (1.231)	-0.572	-3.281	1.873	0.574
Age		-0.042 (0.054)	-0.787	-0.152	0.067	0.437		0.052 (0.066)	0.788	-0.086	0.191	0.441
Log P3	0.086						0.236					
MMSE		0.149 (0.094)	1.586	-0.042	0.34	0.123		-0.179 (0.17)	-1.051	-0.536	0.178	0.306
Gender		-1.331 (0.858)	-1.551	-3.079	0.418	0.131		-0.725 (0.902)	-0.804	-2.612	1.162	0.431
Age		-0.064 (0.053)	-1.194	-0.172	0.045	0.241		0.117 (0.048)	2.408	0.015	0.218	0.026
Log P4	0.073						0.135					
MMSE		0.186 (0.094)	1.966	-0.007	0.378	0.058		-0.273 (0.192)	-1.424	-0.674	0.128	0.171
Gender		-0.881 (0.964)	-1.02	-2.64	0.878	0.315		0.068 (1.013)	0.067	-2.052	2.189	0.947
Age		-0.055 (0.054)	-1.022	-0.164	0.055	0.314		0.102 (0.054)	1.876	-0.012	0.216	0.076
Log O1	0.008						-0.154					
MMSE		0.164 (0.095)	1.724	-0.03	0.358	0.094		-0.015 (0.241)	-0.063	-0.519	0.489	0.951
Gender		-0.229 (0.871)	-0.263	-2.002	1.545	0.794		0.253 (1.273)	0.199	-2.411	2.918	0.845
Age		-0.04 (0.054)	-0.744	-0.151	0.07	0.462		0.013 (0.068)	0.184	-0.131	0.156	0.856
Log O2	0.139						0.095					
MMSE		0.181 (0.091)	1.983	-0.005	0.367	0.056		-0.113 (0.187)	-0.606	-0.504	0.278	0.552
Gender		-1.128 (0.835)	-1.351	-2.828	0.572	0.186		0.462 (0.988)	0.467	-1.606	2.53	0.646
Age		-0.098 (0.052)	-1.883	-0.203	0.008	0.069		0.116 (0.053)	2.191	0.005	0.228	0.041
Log F7	0.001						-0.144					
MMSE		0.165 (0.102)	1.614	-0.043	0.373	0.116		0.118 (0.246)	0.48	-0.397	0.633	0.637
Gender		-0.234 (0.933)	-0.251	-2.135	1.666	0.803		-0.28 (1.301)	-0.215	-3.004	2.443	0.832

262 **Table 4.:** Linear Regression Analysis of EEG Channels and MMSE Scores, Age, and Gender.

Age		-0.051 (0.058)	-0.881	-0.169	0.067	0.385		-0.001 (0.07)	-0.015	-0.148	0.145	0.988
Log F8	0.101						-0.112					
MMSE		0.136 (0.097)	1.411	-0.061	0.333	0.168		0.075 (0.242)	0.308	-0.433	0.582	0.761
Gender		-0.793 (0.884)	-0.898	-2.594	1.007	0.376		-1.089 (1.28)	-0.85	-3.772	1.594	0.406
Age		-0.121 (0.055)	-2.206	-0.233	-0.009	0.035		-0.019 (0.069)	-0.278	-0.163	0.125	0.784
Log T3	0.02						-0.116					
MMSE		0.151 (0.097)	1.552	-0.047	0.348	0.13		0.052 (0.231)	0.224	-0.432	0.536	0.825
Gender		-0.718 (0.887)	-0.809	-2.525	1.09	0.425		-1.011 (1.223)	-0.827	-3.571	1.549	0.419
Age		-0.05 90.056)	-0.912	-0.163	0.062	0.369		-0.002 (0.066)	-0.027	-0.139	0.136	0.979
Log T4	0.072	· ·					-0.144					
MMSE		0.211 (0.096)	2.19	0.015	0.406	0.036		0.054 (0.242)	0.225	-0.452	0.56	0.825
Gender		0.06 (0.879)	0.068	-1.731	1.85	0.946		0.242 (1.278)	0.19	-2.433	2.918	0.852
Age		-0.79 (0.055)	-1.441	-0.19	0.033	0.159		0.021 (0.069)	0.301	-0.123	0.165	0.767
Log T5	0.027						-0.142					
MMSE		0.156 (0.096)	1.629	-0.039	0.351	0.113		-0.059 (0.25)	-0.237	-0.582	0.464	0.815
Gender		-0.852 (0.875)	-0.974	-2.635	0.93	0.337		-0.374 (1.321)	-0.238	-3.139	2.392	0.78
Age		-0.21 (0.054)	-0.386	-0.132	0.09	0.702		-0.009 (0.071)	-0.132	-0.158	0.139	0.896
Log T6	0.067						-0.131	· · ·				
MMSE		0.117 (0.091)	1.285	-0.069	0.303	0.208		-0.031 (0.255)	-0.122	-0.565	0.502	0.904
Gender		-1.031 (0.834)	-1.236	-2.73	0.669	0.226		-0.645 (-0.479)	-0.479	-3.468	2.177	0.638
Age		-0.084 (0.052)	-1.619	-0.19	0.022	0.115		-0.023 (0.073)	-0.318	-0.175	0.129	0.754
Log Fz	0.096						0.059					
MMSE		0.2 (0.092)	2.18	0.013	0.387	0.037		-0.05 (0.1810	-0.278	-0.429	0.329	0.784
Gender		-0.934 (0.839)	-1.113	-2.644	0.776	0.274		-1.237 (0.958)	-1.291	-3.243	0.768	0.212
Age		-0.045 (0.052)	-0.863	-0.151	0.061	0.394		0.061 (0.052)	1.189	-0.047	0.169	0.249
Log Cz	0.006						0.273					
MMSE		0.157 (0.096)	1.628	-0.039	0.353	0.113		-0.299 (0.169)	-1.769	-0.652	0.055	0.093
Gender		-0.458 (0.88)	-0.52	-2.251	1.335	0.606		-1.073 (0.892)	-1.203	-2.941	0.795	0.244
Age		-0.005 (0.055)	-0.097	-0.117	0.106	0.923		0.07 (0.048)	1.461	-0.03	0.171	0.16
Log Pz	0.041						0.183					
MMSE		0.131 (0.094)	1.393	-0.061	0.323	0.173		-0.288 (0.180	-1.599	-0.666	0.089	0.126
Gender		-1.069 (0.86)	-1.244	-2.821	0.682	0.223		-0.268 (0.954)	-0.281	-2.264	1.728	0.782
Age		-0.056 (0.053)	-1.049	-0.165	0.053	0.302		0.095 (0.051)	1.85	-0.012	0.202	0.08

263 In AD, the EEG data analysis revealed that most channels do not show significant correlations with 264 MMSE scores, indicating that cognitive decline as measured by MMSE may not strongly influence EEG 265 patterns in this dataset. Notably, channels like Log C3 (B=2.319 and p=0.027), Log C4 (B=2.012 and p=0.053), Log T4 (B = 2.19, p = 0.036), and Log Fz (B = 2.18, p = 0.037) showed marginally significant 266 267 or significant associations with MMSE scores. Besides, Log C3 (B = 2.319, p = 0.027) showed a 268 significant positive correlation, suggesting that lower MMSE scores (indicating worse cognitive 269 performance) are associated with increased activity in this channel. However, age had mixed effects, with 270 only a few channels like Log F8 (B = -2.206, p = 0.035) showing significant negative correlations, 271 implying that age-related changes in EEG patterns are not uniform across all channels.

In FTD, there was a consistent and significant negative relationship between age and EEG activity across most channels. This suggests that as patients age, there is a marked decline in EEG activity, reflecting the progressive nature of the disease. Channels such as Log Fp1, Log Fp2, Log C3, and Log O2 showed significant negative correlations with age, meaning that older age is associated with reduced EEG activity in these regions. This widespread negative association underscores how aging can impact EEG patterns in FTD patients, potentially reflecting disease-related alterations in brain function.

278 **4. Discussion**

Our study highlighted the distinct relationships between cognitive function, age, and brain activity in AD and FTD. We found that cognitive function using MMSE has a more significant relationship with brain activity in AD, whereas age has a more prominent impact on brain activity in FTD.

As per findings, in AD, the MMSE was a significant predictor of brain activity in regions such as C3, C4, T4, and Fz, indicating a close relationship between cognitive function and activity in these areas. Correlation analysis supported this, showing significant positive associations between MMSE scores and EEG power in Log Fp1, Log T4, and Log Fz, suggesting that better cognitive performance is related to higher EEG power in frontal and temporal regions. Additionally, age was a significant predictor of brain activity in the F8 region, indicating age-related changes in brain activity.

Nonetheless, in FTD, age was a significant predictor of brain activity in regions such as C3, P3, O1, and O2, indicating a more consistent and widespread impact compared to AD. MMSE was not a significant predictor in any region for FTD, suggesting that cognitive function is less related to brain activity in FTD patients. Correlation analysis showed significant negative correlations between MMSE scores and EEG power in Log P3, Log P4, Log Cz, and Log Pz, indicating that higher EEG power in these regions is linked to lower cognitive function in FTD patients.

294 Our findings align with previous research indicating that cognitive decline in AD is associated with 295 specific changes in brain activity, particularly in the frontal and temporal regions [42-47]. Cognitive 296 decline in AD is characterized by a progressive deterioration of cognitive functions, which can be 297 measured using techniques such as EEG. Research has consistently shown that the frontal and temporal 298 regions of the brain are crucial for various cognitive functions [48]. For instance, the frontal regions are 299 involved in executive functions, such as planning, decision-making, problem-solving, and controlling 300 behavior [49, 50], while the temporal regions play a significant role in memory and language processing, containing structures like the hippocampus, which is critical for forming and retrieving memories [51-53]. 301

In AD, the frontal and temporal regions are among the first to show significant pathological changes, including the accumulation of amyloid plaques and neurofibrillary tangles. These pathological changes lead to neuron damage and death, resulting in impairments in memory, executive function, and language. Patients struggle with forming new memories and recalling past events, face difficulties with tasks requiring planning and organization, and experience challenges with word finding and understanding language [54-56].

Our study found significant positive correlations between MMSE scores and EEG power in regions such as Fp1 (frontal pole 1), T4 (right temporal lobe), and Fz (midline frontal). These findings reinforce the understanding that specific changes in brain activity, detectable through EEG, are related to cognitive decline in AD. Researchers, by identifying these correlations, can better understand the neural mechanisms underlying cognitive decline and potentially develop targeted interventions to slow or mitigate the effects of AD.

314 Another study found that Neurometric QEEG measures, particularly increased theta power and delta 315 power in later stages, are sensitive indicators of cognitive impairment, especially significant in a bilateral 316 temporo-parietal arc, suggesting their potential utility in the early evaluation of dementia and estimation 317 of cognitive deterioration in Alzheimer's type dementia patients [57]. Likewise, cognitive impairment in 318 patients with epilepsy (PWE) was significantly associated with QEEG measures, particularly 319 interhemispheric delta and beta coherences, suggesting that QEEG may be useful in understanding the 320 pathophysiological basis of cognitive alterations in epilepsy [58]. Notably, a former study found that there 321 are significant gender differences in brain organization and functioning, with women displaying higher 322 interhemispheric synchronization and lower hemispheric differentiation than men. This means that, in 323 women, higher interhemispheric correlation was positively associated with abstract and spatial aptitude 324 scores in the central cortex, whereas in men, it was negatively associated with spatial, abstract, and verbal 325 aptitude scores across most recorded brain regions [59].

Our results in FTD align with earlier studies that indicate a broader impact of age on brain activity [24, 60]. Unlike AD, where specific brain regions were primarily affected, FTD showed a more diffuse pattern of brain activity changes. This broader impact may reflect the different underlying mechanisms of FTD compared to AD, where the disease pathology is not confined to specific areas but rather spreads more widely across the brain.

331 In FTD, we did not observe a significant relationship between MMSE scores and brain activity. This finding is consistent with the understanding that FTD affects the brain more diffusely, disrupting 332 333 cognitive functions in a less region-specific manner. The MMSE, while useful in assessing general 334 cognitive function, may not be as effective in capturing the complex and widespread brain changes 335 occurring in FTD. Interestingly, we found negative correlations between MMSE scores and EEG power 336 in the parietal regions (P3, P4, Cz, Pz). These regions are involved in various cognitive processes, 337 including spatial orientation, sensory perception, and integration of sensory information. The negative 338 correlations suggest that higher cognitive impairment in FTD is associated with increased EEG power in 339 these areas. This could indicate compensatory neural activity or pathological overactivation in response to 340 neurodegenerative changes.

Aging contributes to the development and progression of dementia through a combination of cellular and molecular mechanisms [24, 61, 62]. At the cellular level, increased oxidative stress [63-65], mitochondrial dysfunction [66, 67], and impaired autophagy [68] lead to the accumulation of damaged proteins and organelles, causing neuronal damage. Chronic inflammation and immune response dysregulation further exacerbate neurodegeneration [68-70]. Thus, understanding these mechanisms provides insights into the complex relationship between aging and dementia, potentially guiding the development of targeted therapies to mitigate age-related cognitive decline.

The implications of the current study are twofold. First, it emphasizes the importance of specific brain regions in cognitive performance, suggesting potential targets for neurostimulation or other therapeutic interventions aimed at enhancing cognitive function. Second, it underscores the need for a nuanced approach in analyzing EEG data, recognizing that not all brain regions equally contribute to cognitive abilities as measured by global scales like the MMSE.

Future studies should consider several key limitations and confounders when investigating the relationship between EEG activity and cognitive function, as observed in this study. These include potential constraints related to sample size and generalizability, given the need for larger and more diverse participant cohorts to ensure robust findings across different populations. Notice that addressing selection biases in participant recruitment and standardizing electrode placement and signal interpretation

358 methods are crucial to minimize variability in EEG data. Moreover, considering the influence of 359 medications, comorbidities, and participant characteristics on EEG readings and cognitive outcomes is 360 essential for accurate interpretation. Methodologically, future research could benefit from integrating 361 multimodal imaging techniques such as fMRI or PET and advanced statistical analyses to explore 362 network dynamics and uncover nuanced associations between brain regions and specific cognitive 363 domains. Thus, by addressing these factors, future studies can enhance the reliability and applicability of 364 findings in understanding the neural underpinnings of cognitive function across various neurological 365 conditions.

5. Conclusion

This study aimed to investigate regional differences in EEG patterns among AD and FTD cases to 367 enhance diagnostic strategies. It highlighted distinct relationships between cognitive function, age, and 368 369 brain activity in AD and FTD. In AD, cognitive function measured by MMSE scores significantly 370 predicted brain activity, particularly in the frontal and temporal regions, indicating a close relationship 371 between cognitive performance and EEG power in these areas. Conversely, in FTD, age was a more 372 significant predictor of brain activity, with a consistent and widespread impact across multiple brain 373 regions. The findings suggest that EEG biomarkers can enhance diagnostic strategies by highlighting 374 different patterns of brain activity related to cognitive function and age in AD and FTD.

375

376

377

378

- 379
- 380
- 381
- 382
- 383
- 384
- 385
- 386
- 387

Page 20 of 25

388

389 Abbreviations

- **EEG:** electroencephalography; **AD:** Alzheimer's disease; **FTD:** frontotemporal dementia; **MMSE:** Mini-
- 391 Mental State Examination.
- 392
- 393

394

Declarations section:

Acknowledgments: We acknowledge data descriptor (<u>https://doi.org/10.3390/data8060095</u>) and
 OpenNeuro that provided this data.

398 Ethical Approval and Consent to Participate: The study was conducted in accordance with the 399 Declaration of Helsinki and approved by the Scientific and Ethics Committee of AHEPA University 400 Hospital, Aristotle University of Thessaloniki, under protocol number 142/12-04-2023.

401 **Consent for Publication:** Not applicable.

402 **Authors' Contributions:** All authors listed have made a substantial, direct, and intellectual contribution 403 to the work, and approved it for publication. A.A and H.N. contributed to developing research ideas and 404 analysis. A.A., H.N., and F.A. contributed to interpretation of data, writing the draft, and revising it. All 405 authors read and approved the final manuscript.

- 406 Availability of Data and Materials: The data for this article were obtained from OpenNeuro Dataset
 407 ds004504. Dataset DOI is <u>https://doi.org/10.18112/openneuro.ds004504.v1.0.7</u>.
- 408 **Funding**: Not applicable.
- 409 **Competing Interests:** There are no conflicting interests to be stated.
- 410
- 411
- 412
- 440
- 413
- 414

415 **References**

- 416 1. Popov T, Tröndle M, Baranczuk-Turska Z, Pfeiffer C, Haufe S, Langer N. Test–retest reliability of
- 417 resting-state EEG in young and older adults. Psychophysiology. 2023;60(7):e14268.
- 418 2. Da Silva FL. EEG: origin and measurement. EEG-fMRI: physiological basis, technique, and applications.
- 419 Springer; 2023. p. 23-48.
- 420 3. Perez V, Duque A, Hidalgo V, Salvador A. EEG Frequency Bands in Subjective Cognitive Decline: A
- 421 Systematic Review of Resting State Studies. Biological Psychology. 2024:108823.

- 422 4. Ward D, Jones R, Bones PJ, Carroll G. Enhancement of deep epileptiform activity in the EEG via 3-D
- 423 adaptive spatial filtering. IEEE transactions on bio-medical engineering. 1999;46:707-16. doi:

424 10.1109/10.764947.

- 425 5. Babiloni C, Triggiani Al, Lizio R, Cordone S, Tattoli G, Bevilacqua V, et al. Classification of Single Normal
- 426 and Alzheimer's Disease Individuals from Cortical Sources of Resting State EEG Rhythms. Frontiers in
- 427 Neuroscience. 2016;10. doi: 10.3389/fnins.2016.00047.
- 428 6. Kim S-E, Shin C, Yim J, Seo K, Ryu H, Choi H, et al. Resting-state electroencephalographic
- 429 characteristics related to mild cognitive impairments. Frontiers in Psychiatry. 2023;14. doi:
- 430 10.3389/fpsyt.2023.1231861.
- 431 7. Zheng X, Wang B, Liu H, Wu W, Sun J, Fang W, et al. Diagnosis of Alzheimer's disease via resting-state
- 432 EEG: integration of spectrum, complexity, and synchronization signal features. Frontiers in Aging 433 Neuroscience. 2023;15. doi: 10.3389/fnagi.2023.1288295.
- 434 8. Cassani R, Estarellas M, San-Martin R, Fraga FJ, Falk TH. Systematic Review on Resting-State EEG for
- Alzheimer's Disease Diagnosis and Progression Assessment. Dis Markers. 2018;2018:5174815. doi:
 10.1155/2018/5174815.
- 437 9. Aoki Y, Takahashi R, Suzuki Y, Pascual-Marqui RD, Kito Y, Hikida S, et al. EEG resting-state networks in
- Alzheimer's disease associated with clinical symptoms. Scientific Reports. 2023;13(1):3964. doi:
- 439 10.1038/s41598-023-30075-3.
- 440 10. Kopčanová M, Tait L, Donoghue T, Stothart G, Smith L, Flores-Sandoval AA, et al. Resting-state EEG
- signatures of Alzheimer's disease are driven by periodic but not aperiodic changes. Neurobiol Dis.
- 442 2024;190:106380. doi: 10.1016/j.nbd.2023.106380.
- 11. Nardone R, Sebastianelli L, Versace V, Saltuari L, Lochner P, Frey V, et al. Usefulness of EEG
- Techniques in Distinguishing Frontotemporal Dementia from Alzheimer's Disease and Other Dementias.
 Dis Markers. 2018;2018:6581490. doi: 10.1155/2018/6581490.
- 446 12. Lal U, Chikkankod AV, Longo L. A Comparative Study on Feature Extraction Techniques for the
- 447 Discrimination of Frontotemporal Dementia and Alzheimer's Disease with Electroencephalography in
- 448 Resting-State Adults. Brain Sciences. 2024 doi: 10.3390/brainsci14040335.
- 13. Si Y, He R, Jiang L, Yao D, Zhang H, Xu P, et al. Differentiating Between Alzheimer's Disease and
- 450 Frontotemporal Dementia Based on the Resting-State Multilayer EEG Network. IEEE Transactions on
- 451 Neural Systems and Rehabilitation Engineering. 2023;31:4521-7. doi: 10.1109/TNSRE.2023.3329174.
- 452 14. Moretti DV, paternicò d, Binetti G, Zanetti O, Frisoni gb. EEG upper/low alpha frequency power ratio
- relates to temporo-parietal brain atrophy and memory performances in mild cognitive impairment.
- 454 Frontiers in Aging Neuroscience. 2013;5. doi: 10.3389/fnagi.2013.00063.
- 455 15. Lejko N, Larabi DI, Herrmann CS, Aleman A, Ćurčić-Blake B. Alpha Power and Functional Connectivity
- 456 in Cognitive Decline: A Systematic Review and Meta-Analysis. J Alzheimers Dis. 2020;78(3):1047-88. doi:
 457 10.3233/jad-200962.
- 458 16. Jiao B, Li R, Zhou H, Qing K, Liu H, Pan H, et al. Neural biomarker diagnosis and prediction to mild
- 459 cognitive impairment and Alzheimer's disease using EEG technology. Alzheimer's Research & Therapy.
 460 2023;15(1):32. doi: 10.1186/s13195-023-01181-1.
- 461 17. Arevalo-Rodriguez I, Smailagic N, Roqué-Figuls M, Ciapponi A, Sanchez-Perez E, Giannakou A, et al.
- 462 Mini-Mental State Examination (MMSE) for the early detection of dementia in people with mild
- 463 cognitive impairment (MCI). Cochrane Database Syst Rev. 2021;7(7):Cd010783. doi:
- 464 10.1002/14651858.CD010783.pub3.
- 465 18. Arevalo-Rodriguez I, Smailagic N, Roqué IFM, Ciapponi A, Sanchez-Perez E, Giannakou A, et al. Mini-
- 466 Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in
- 467 people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2015;2015(3):Cd010783. doi:
- 468 10.1002/14651858.CD010783.pub2.

- 19. Torabinikjeh M, Asayesh V, Dehghani M, Kouchakzadeh A, Marhamati H, Gharibzadeh S. Correlations
- 470 of frontal resting-state EEG markers with MMSE scores in patients with Alzheimer's disease. The
- 471 Egyptian Journal of Neurology, Psychiatry and Neurosurgery. 2022;58(1):31. doi: 10.1186/s41983-022472 00465-x.
- 473 20. Lee SJ, Park MH, Park SS, Ahn JY, Heo JH. Quantitative EEG and medial temporal lobe atrophy in
- 474 Alzheimer's dementia: Preliminary study. Ann Indian Acad Neurol. 2015;18(1):10-4. doi: 10.4103/0972-475 2327.145284.
- 476 21. Xu M, Zhang Y, Zhang Y, Liu X, Qing K. EEG biomarkers analysis in different cognitive impairment
- 477 after stroke: an exploration study. Front Neurol. 2024;15:1358167. doi: 10.3389/fneur.2024.1358167.
- 478 22. Araújo T, Teixeira J, Rodrigues P. Smart-Data-Driven System for Alzheimer Disease Detection through
- 479 Electroencephalographic Signals. Bioengineering. 2022;9:141. doi: 10.3390/bioengineering9040141.
- 480 23. Caravaglios G, Muscoso EG, Blandino V, Di Maria G, Gangitano M, Graziano F, et al. EEG Resting-
- 481 State Functional Networks in Amnestic Mild Cognitive Impairment. Clinical EEG and Neuroscience.
- 482 2022;54(1):36-50. doi: 10.1177/15500594221110036.
- 483 24. Lee J, Kim H-J. Normal Aging Induces Changes in the Brain and Neurodegeneration Progress: Review
- 484 of the Structural, Biochemical, Metabolic, Cellular, and Molecular Changes. Frontiers in Aging
 485 Neuroscience. 2022;14. doi: 10.3389/fnagi.2022.931536.
- 486 25. Pavlov AN, Pitsik EN, Frolov NS, Badarin A, Pavlova ON, Hramov AE. Age-Related Distinctions in EEG
- 487 Signals during Execution of Motor Tasks Characterized in Terms of Long-Range Correlations. Sensors
 488 (Basel). 2020;20(20). doi: 10.3390/s20205843.
- 489 26. Javaid H, Kumarnsit E, Chatpun S. Age-Related Alterations in EEG Network Connectivity in Healthy
 490 Aging. Brain Sci. 2022;12(2). doi: 10.3390/brainsci12020218.
- 491 27. He M, Liu F, Nummenmaa A, Hämäläinen M, Dickerson BC, Purdon PL. Age-Related EEG Power
- 492 Reductions Cannot Be Explained by Changes of the Conductivity Distribution in the Head Due to Brain
- 493 Atrophy. Frontiers in Aging Neuroscience. 2021;13. doi: 10.3389/fnagi.2021.632310.
- 494 28. Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, Bohr VA. Ageing as a risk factor for
- 495 neurodegenerative disease. Nat Rev Neurol. 2019;15(10):565-81. doi: 10.1038/s41582-019-0244-7.
- 496 29. Kesidou E, Theotokis P, Damianidou O, Boziki M, Konstantinidou N, Taloumtzis C, et al. CNS Ageing in
- 497 Health and Neurodegenerative Disorders. J Clin Med. 2023;12(6). doi: 10.3390/jcm12062255.
- 498 30. Kopčanová M, Tait L, Donoghue T, Stothart G, Smith L, Sandoval AAF, et al. Resting-state EEG
- 499 signatures of Alzheimer's disease are driven by periodic but not aperiodic changes. bioRxiv. 2023. doi:
 500 10.1101/2023.06.11.544491.
- 501 31. Merkin A, Sghirripa S, Graetz L, Smith AE, Hordacre B, Harris R, et al. Do age-related differences in
- aperiodic neural activity explain differences in resting EEG alpha? Neurobiology of Aging. 2023;121:7887. doi: https://doi.org/10.1016/j.neurobiolaging.2022.09.003.
- 505 87. doi. <u>Inteps.//doi.org/10.1010/j.neurobiologing.2022.09.005</u>.
- 32. Fröhlich S, Kutz DF, Müller K, Voelcker-Rehage C. Characteristics of Resting State EEG Power in 80+-
- 505 Year-Olds of Different Cognitive Status. Frontiers in Aging Neuroscience. 2021;13. doi:
- 506 10.3389/fnagi.2021.675689.
- 507 33. Toepper M. Dissociating Normal Aging from Alzheimer's Disease: A View from Cognitive
- 508 Neuroscience. J Alzheimers Dis. 2017;57(2):331-52. doi: 10.3233/jad-161099.
- 509 34. Gao S, Hendrie HC, Hall KS, Hui S. The Relationships Between Age, Sex, and the Incidence of
- 510 Dementia and Alzheimer Disease: A Meta-analysis. Archives of General Psychiatry. 1998;55(9):809-15.
- 511 doi: 10.1001/archpsyc.55.9.809.
- 512 35. Qiu C, Fratiglioni L. Aging without dementia is achievable: current evidence from epidemiological
- research. Journal of Alzheimer's Disease. 2018;62(3):933-42.
- 514 36. Nelson PT, Head E, Schmitt FA, Davis PR, Neltner JH, Jicha GA, et al. Alzheimer's disease is not "brain
- aging": neuropathological, genetic, and epidemiological human studies. Acta neuropathologica.
- 516 2011;121:571-87.

- 517 37. Miltiadous A, Tzimourta KD, Afrantou T, Ioannidis P, Grigoriadis N, Tsalikakis DG, et al. A Dataset of
- 518 Scalp EEG Recordings of Alzheimer's Disease, Frontotemporal Dementia and Healthy Subjects from
- 519 Routine EEG. Data. 2023 doi: 10.3390/data8060095.
- 520 38. Delorme A, Sejnowski T, Makeig S. Enhanced detection of artifacts in EEG data using higher-order
- 521 statistics and independent component analysis. Neuroimage. 2007;34(4):1443-9. doi:
- 522 10.1016/j.neuroimage.2006.11.004.
- 523 39. Miltiadous A, Tzimourta KD, Giannakeas N, Tsipouras MG, Afrantou T, Ioannidis P, Tzallas AT.
- 524 Alzheimer's Disease and Frontotemporal Dementia: A Robust Classification Method of EEG Signals and a
- 525 Comparison of Validation Methods. Diagnostics (Basel). 2021;11(8). doi: 10.3390/diagnostics11081437.
- 40. Solomon Jr OM. PSD computations using Welch's method. NASA STI/Recon Technical Report N.
 1991;92:23584.
- 41. Kurlowicz L, Wallace M. The Mini-Mental State Examination (MMSE). J Gerontol Nurs. 1999;25(5):89. doi: 10.3928/0098-9134-19990501-08.
- 42. Beason-Held LL, Goh JO, An Y, Kraut MA, O'Brien RJ, Ferrucci L, Resnick SM. Changes in brain
- 531 function occur years before the onset of cognitive impairment. J Neurosci. 2013;33(46):18008-14. doi:
- 532 10.1523/jneurosci.1402-13.2013.
- 43. Chouliaras L, O'Brien JT. The use of neuroimaging techniques in the early and differential diagnosis
- of dementia. Molecular Psychiatry. 2023;28(10):4084-97. doi: 10.1038/s41380-023-02215-8.
- 44. Ribarič S. Detecting Early Cognitive Decline in Alzheimer's Disease with Brain Synaptic Structural and
- 536 Functional Evaluation. Biomedicines. 2023 doi: 10.3390/biomedicines11020355.
- 45. Talwar P, Kushwaha S, Chaturvedi M, Mahajan V. Systematic review of different neuroimaging
- 538 correlates in mild cognitive impairment and Alzheimer's disease. Clinical neuroradiology.
- 539 2021;31(4):953-67.
- 46. Zhang H, Wang Y, Lyu D, Li Y, Li W, Wang Q, et al. Cerebral blood flow in mild cognitive impairment
- and Alzheimer's disease: A systematic review and meta-analysis. Ageing research reviews.
- 542 2021;71:101450.
- 47. Sun J, Wang B, Niu Y, Tan Y, Fan C, Zhang N, et al. Complexity analysis of EEG, MEG, and fMRI in mild
 cognitive impairment and Alzheimer's disease: a review. Entropy. 2020;22(2):239.
- 545 48. Jung J, Cloutman LL, Binney RJ, Lambon Ralph MA. The structural connectivity of higher order
- association cortices reflects human functional brain networks. Cortex. 2017;97:221-39. doi:
- 547 10.1016/j.cortex.2016.08.011.
- 49. Friedman NP, Robbins TW. The role of prefrontal cortex in cognitive control and executive function.
 Neuropsychopharmacology. 2022;47(1):72-89. doi: 10.1038/s41386-021-01132-0.
- 550 50. Takeuchi H, Taki Y, Sassa Y, Hashizume H, Sekiguchi A, Fukushima A, Kawashima R. Brain structures
- associated with executive functions during everyday events in a non-clinical sample. Brain Struct Funct.
- 552 2013;218(4):1017-32. doi: 10.1007/s00429-012-0444-z.
- 553 51. Ullman MT. Contributions of memory circuits to language: the declarative/procedural model.
- 554 Cognition. 2004;92(1):231-70. doi: <u>https://doi.org/10.1016/j.cognition.2003.10.008</u>.
- 555 52. Busch RM, Yehia L, Blümcke I, Hu B, Prayson R, Hermann BP, et al. Molecular and subregion
- 556 mechanisms of episodic memory phenotypes in temporal lobe epilepsy. Brain Commun.
- 557 2022;4(6):fcac285. doi: 10.1093/braincomms/fcac285.
- 558 53. Wiltgen BJ, Zhou M, Cai Y, Balaji J, Karlsson MG, Parivash SN, et al. The hippocampus plays a
- selective role in the retrieval of detailed contextual memories. Curr Biol. 2010;20(15):1336-44. doi:
- 560 10.1016/j.cub.2010.06.068.
- 561 54. Perry R, Hodges J. Differentiating frontal and temporal variant frontotemporal dementia from
- 562 Alzheimer's disease. Neurology. 2000;54(12):2277-84.

- 563 55. Kumfor F, Irish M, Hodges JR, Piguet O. Frontal and temporal lobe contributions to emotional
- enhancement of memory in behavioral-variant frontotemporal dementia and Alzheimer's disease.
- 565 Frontiers in behavioral neuroscience. 2014;8:225.
- 566 56. Berron D, van Westen D, Ossenkoppele R, Strandberg O, Hansson O. Medial temporal lobe
- 567 connectivity and its associations with cognition in early Alzheimer's disease. Brain. 2020;143(4):1233-48.
- 568 57. Prichep LS, John ER, Ferris SH, Reisberg B, Almas M, Alper K, Cancro R. Quantitative EEG correlates of
- 569 cognitive deterioration in the elderly. Neurobiology of Aging. 1994;15(1):85-90. doi:
- 570 https://doi.org/10.1016/0197-4580(94)90147-3.
- 571 58. Tedrus GM, Negreiros LM, Ballarim RS, Marques TA, Fonseca LC. Correlations Between Cognitive
- 572 Aspects and Quantitative EEG in Adults With Epilepsy. Clinical EEG and Neuroscience. 2018;50(5):348-
- 573 53. doi: 10.1177/1550059418793553.
- 574 59. Corsi-cabrera M, Herrera P, Malvido M. Correlation Between Eeg and Cognitive Abilities: Sex
- 575 Differences. International Journal of Neuroscience. 1989;45(1-2):133-41. doi:
- 576 10.3109/00207458908986226.
- 577 60. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and
- 578 dementia. New England Journal of Medicine. 2009;360(22):2302-9.
- 579 61. Gonzales MM, Garbarino VR, Pollet E, Palavicini JP, Kellogg DL, Kraig E, Orr ME. Biological aging
- 580 processes underlying cognitive decline and neurodegenerative disease. The Journal of clinical 581 investigation. 2022;132(10).
- 582 62. Wu JW, Yaqub A, Ma Y, Koudstaal W, Hofman A, Ikram MA, et al. Biological age in healthy elderly 583 predicts aging-related diseases including dementia. Scientific reports. 2021;11(1):15929.
- 584 63. Mecocci P, Boccardi V. The impact of aging in dementia: It is time to refocus attention on the main 585 risk factor of dementia. Ageing research reviews. 2021;65:101210.
- 586 64. Fang X, Crumpler RF, Thomas KN, Mazique JN, Roman RJ, Fan F. Contribution of cerebral
- 587 microvascular mechanisms to age-related cognitive impairment and dementia. Physiology international. 588 2022;109(1):20-30.
- 589 65. Ton AMM, Campagnaro BP, Alves GA, Aires R, Côco LZ, Arpini CM, et al. Oxidative stress and
- 590 dementia in Alzheimer's patients: effects of synbiotic supplementation. Oxidative medicine and cellular 591 longevity. 2020;2020(1):2638703.
- 592 66. Ashleigh T, Swerdlow RH, Beal MF. The role of mitochondrial dysfunction in Alzheimer's disease 593 pathogenesis. Alzheimer's & Dementia. 2023;19(1):333-42.
- 67. Sharma C, Kim S, Nam Y, Jung UJ, Kim SR. Mitochondrial dysfunction as a driver of cognitive
- impairment in Alzheimer's disease. International Journal of Molecular Sciences. 2021;22(9):4850.
- 596 68. Karabiyik C, Frake RA, Park SJ, Pavel M, Rubinsztein DC. Autophagy in ageing and ageing-related
- 597 neurodegenerative diseases. Ageing Neurodegener Dis. 2021;1(2).
- 598 69. Wang X-X, Zhang B, Xia R, Jia Q-Y. Inflammation, apoptosis and autophagy as critical players in
- vascular dementia. European Review for Medical & Pharmacological Sciences. 2020;24(18).
- 600 70. Lutshumba J, Nikolajczyk BS, Bachstetter AD. Dysregulation of systemic immunity in aging and
- dementia. Frontiers in Cellular Neuroscience. 2021;15:652111.

602

603

604